AZN up +1.23% percent right now. $AZN High is at 74.18 and the Low 73.75 with current volume of 440,876.
Recent News posted below.
AZN Astrazeneca Plc Recent Headline News
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - 30 mins ago
SHPG: 201.99 (+1.01), PFE: 30.25 (+0.05), AZN: 74.29 (+1.08), ABBV: 63.61 (-0.18), WAG: 67.31 (-0.47)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 42 mins ago
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 324.03 (-3.84), AZN: 74.29 (+1.08), LLY: 67.99 (-0.36), AEGR: 21.71 (+0.14), GSK: 45.82 (+0.66)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - 2 hrs 43 mins ago
MRK: 59.34 (+0.53), AZN: 74.29 (+1.08), THRX: 13.06 (-0.38), TBPH: 18.02 (-0.30), GSK: 45.82 (+0.66)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 117.25 (+0.31), GILD: 108.34 (+1.32), MRK: 59.34 (+0.53), DNDN: 0.15 (-0.03), AZN: 74.29 (+1.08), TEVA: 58.20 (+0.16), ABBV: 63.61 (-0.18), GSK: 45.82 (+0.66), BMY: 58.69 (-0.12), NVS: 92.68 (+0.05)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.90 (+0.08), PFE: 30.25 (+0.05), MRK: 59.34 (+0.53), AZN: 74.29 (+1.08), LLY: 67.99 (-0.36), GSK: 45.82 (+0.66)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.07 (+0.02), NVO: 44.25 (+0.95), AZN: 74.29 (+1.08), SLXP: 98.18 (+4.31), NVS: 92.68 (+0.05)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.34 (+0.53), AZN: 74.29 (+1.08), AMGN: 162.45 (-0.64), TEVA: 58.20 (+0.16), THRX: 13.06 (-0.38), GSK: 45.82 (+0.66), SNY: 47.10 (+0.91), REGN: 398.37 (+12.40), NVS: 92.68 (+0.05)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.29 (+1.08), GSK: 45.82 (+0.66), NVS: 92.68 (+0.05), EXEL: 1.79 (unch)
FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST
IPO: 23.47 (-0.10), BIS: 50.10 (-0.25), BIB: 120.45 (+0.37), AZN: 74.29 (+1.08), IBB: 295.96 (+0.76), FGEN: ()
Nektar Therapeutics Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 11:20AM CST
Nektar (NKTR) reported third-quarter 2014 earnings of 53 cents per share, beating the Zacks Consensus Estimate of 39 cents.
BAX: 70.49 (-0.14), AUXL: 32.48 (-0.22), AZN: 74.29 (+1.08), NKTR: 13.79 (unch)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.98 (-0.41), LLY: 67.99 (-0.36), CNCE: 13.21 (-0.16), OPK: 8.49 (-0.14), AZN: 74.29 (+1.08), ALXN: 194.75 (-1.05), ICPT: 171.40 (-4.95), NPSP: 29.50 (+2.59), XLRN: 33.39 (+1.13)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.25 (+0.05), AZN: 74.29 (+1.08), GSK: 45.82 (+0.66)
AstraZeneca Group's (AZN) CEO Pascal Soriot on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:48PM CST
AZN: 74.29 (+1.08)
Time to Sell These 5 'Toxic' Stocks: AstraZeneca, DigitalGlobe and More
at The Street - Fri Nov 07, 2:49PM CST
Guess what? Stock selection matters more than ever in 2014.
HCA: 65.98 (+0.23), TLK: 44.50 (+0.78), FITB: 20.17 (-0.01), DGI: 28.22 (-0.42), AZN: 74.29 (+1.08)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.30 (+0.06), AZN: 74.29 (+1.08), ABBV: 63.61 (-0.18), AEGR: 21.71 (+0.14)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.90 (+0.08), PCYC: 134.11 (+0.13), GILD: 108.34 (+1.32), AZN: 74.29 (+1.08), GSK: 45.82 (+0.66), BMY: 58.69 (-0.12), CELG: 107.64 (-0.37)
Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 107.57 (-1.38), AOL: 45.06 (+0.42), AZN: 74.29 (+1.08)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 201.99 (+1.01), PFE: 30.25 (+0.05), MRK: 59.35 (+0.54), AZN: 74.29 (+1.08), TEVA: 58.20 (+0.16), ITCI: 15.58 (-0.16), ABBV: 63.61 (-0.18), BMY: 58.69 (-0.12), OMER: 19.02 (+1.53)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.18 (-0.06), FURX: 104.77 (-1.41), SYN: 1.45 (+0.02), IRWD: 14.04 (+0.20), LXRX: 1.39 (-0.01), AZN: 74.29 (+1.08), TEVA: 58.20 (+0.16)
Recent News posted below.
AZN Astrazeneca Plc Recent Headline News
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - 30 mins ago
SHPG: 201.99 (+1.01), PFE: 30.25 (+0.05), AZN: 74.29 (+1.08), ABBV: 63.61 (-0.18), WAG: 67.31 (-0.47)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 42 mins ago
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 324.03 (-3.84), AZN: 74.29 (+1.08), LLY: 67.99 (-0.36), AEGR: 21.71 (+0.14), GSK: 45.82 (+0.66)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - 2 hrs 43 mins ago
MRK: 59.34 (+0.53), AZN: 74.29 (+1.08), THRX: 13.06 (-0.38), TBPH: 18.02 (-0.30), GSK: 45.82 (+0.66)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 117.25 (+0.31), GILD: 108.34 (+1.32), MRK: 59.34 (+0.53), DNDN: 0.15 (-0.03), AZN: 74.29 (+1.08), TEVA: 58.20 (+0.16), ABBV: 63.61 (-0.18), GSK: 45.82 (+0.66), BMY: 58.69 (-0.12), NVS: 92.68 (+0.05)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.90 (+0.08), PFE: 30.25 (+0.05), MRK: 59.34 (+0.53), AZN: 74.29 (+1.08), LLY: 67.99 (-0.36), GSK: 45.82 (+0.66)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.07 (+0.02), NVO: 44.25 (+0.95), AZN: 74.29 (+1.08), SLXP: 98.18 (+4.31), NVS: 92.68 (+0.05)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.34 (+0.53), AZN: 74.29 (+1.08), AMGN: 162.45 (-0.64), TEVA: 58.20 (+0.16), THRX: 13.06 (-0.38), GSK: 45.82 (+0.66), SNY: 47.10 (+0.91), REGN: 398.37 (+12.40), NVS: 92.68 (+0.05)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.29 (+1.08), GSK: 45.82 (+0.66), NVS: 92.68 (+0.05), EXEL: 1.79 (unch)
FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST
IPO: 23.47 (-0.10), BIS: 50.10 (-0.25), BIB: 120.45 (+0.37), AZN: 74.29 (+1.08), IBB: 295.96 (+0.76), FGEN: ()
Nektar Therapeutics Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 11:20AM CST
Nektar (NKTR) reported third-quarter 2014 earnings of 53 cents per share, beating the Zacks Consensus Estimate of 39 cents.
BAX: 70.49 (-0.14), AUXL: 32.48 (-0.22), AZN: 74.29 (+1.08), NKTR: 13.79 (unch)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.98 (-0.41), LLY: 67.99 (-0.36), CNCE: 13.21 (-0.16), OPK: 8.49 (-0.14), AZN: 74.29 (+1.08), ALXN: 194.75 (-1.05), ICPT: 171.40 (-4.95), NPSP: 29.50 (+2.59), XLRN: 33.39 (+1.13)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.25 (+0.05), AZN: 74.29 (+1.08), GSK: 45.82 (+0.66)
AstraZeneca Group's (AZN) CEO Pascal Soriot on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:48PM CST
AZN: 74.29 (+1.08)
Time to Sell These 5 'Toxic' Stocks: AstraZeneca, DigitalGlobe and More
at The Street - Fri Nov 07, 2:49PM CST
Guess what? Stock selection matters more than ever in 2014.
HCA: 65.98 (+0.23), TLK: 44.50 (+0.78), FITB: 20.17 (-0.01), DGI: 28.22 (-0.42), AZN: 74.29 (+1.08)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.30 (+0.06), AZN: 74.29 (+1.08), ABBV: 63.61 (-0.18), AEGR: 21.71 (+0.14)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.90 (+0.08), PCYC: 134.11 (+0.13), GILD: 108.34 (+1.32), AZN: 74.29 (+1.08), GSK: 45.82 (+0.66), BMY: 58.69 (-0.12), CELG: 107.64 (-0.37)
Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 107.57 (-1.38), AOL: 45.06 (+0.42), AZN: 74.29 (+1.08)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 201.99 (+1.01), PFE: 30.25 (+0.05), MRK: 59.35 (+0.54), AZN: 74.29 (+1.08), TEVA: 58.20 (+0.16), ITCI: 15.58 (-0.16), ABBV: 63.61 (-0.18), BMY: 58.69 (-0.12), OMER: 19.02 (+1.53)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.18 (-0.06), FURX: 104.77 (-1.41), SYN: 1.45 (+0.02), IRWD: 14.04 (+0.20), LXRX: 1.39 (-0.01), AZN: 74.29 (+1.08), TEVA: 58.20 (+0.16)
